Novavax Inc NVAX.O said on Friday it expects to provide a COVID-19 vaccine targeting Omicron in the fourth quarter as it accelerates the development of shots to protect against the BA.4 and BA.5 subvariants.

The U.S. FDA on Thursday recommended COVID-19 vaccine manufacturers change the design of their booster shots beginning this fall to include components tailored to combat the currently dominant Omicron BA.4 and BA.5 subvariants.


Click to play video: 'How reliable are rapid antigen tests against Omicron?'







How reliable are rapid antigen tests against Omicron?


How reliable are rapid antigen tests against Omicron? – Apr 18, 2022

Novavax expects additional preclinical data on shots tailored against the fast-spreading Omicron subvariants in late summer or fall.

Story continues below advertisement

The company’s vaccine, based on an earlier strain of the virus, has not yet been authorized in the United States and is currently under U.S. Food and Drug Administration review.

(Reporting by Mrinalika Roy in Bengaluru; Editing by Shounak Dasgupta)





Source link

Leave a Reply

Your email address will not be published.

Home  Articles  Disclaimer  Contact Us

© 2022 MyTeensHealth.com - All Rights Reserved.